文献速递治疗药物监测与药物基因组学药物不良反应与药物警戒

阿立哌唑与奥氮平对瞳孔光反射的影响及其与药物基因组学的关系:一项随机多剂量试验

The effects of aripiprazole and olanzapine on pupillary light reflex and its relationship with pharmacogenetics in a randomized multiple-dose trial.
PubMed 文献 · Br J Clin Pharmacol · 2020-04-27

多种基因多态性影响瞳孔测量参数及药物药代动力学。

要点

  • 阿立哌唑多次给药后先引起瞳孔扩大,随后每次给药引起收缩,并改变所有瞳孔测量参数(P < .05)。
  • 奥氮平仅改变最小瞳孔尺寸(P = .046),未引起其他瞳孔参数显著变化。
  • CYP2D6、CYP3A、CYP1A2、ABCB1和UGT1A1基因多态性显著影响阿立哌唑、脱氢阿立哌唑和奥氮平的血药浓度。

核心结论

  • 阿立哌唑及其主要代谢物脱氢阿立哌唑改变瞳孔收缩,而奥氮平无此效应。
  • 多种基因多态性可能影响瞳孔测量参数,且若干多态性影响阿立哌唑、脱氢阿立哌唑和奥氮平的药代动力学。
  • 瞳孔测量法可能是确定抗精神病药物治疗期间自主神经活动的有用工具。

研究设计与样本

  • 通过定量聚合酶链反应对46个多态性进行基因分型。
  • 使用自动瞳孔测量法进行瞳孔检查。
  • 采用高效液相色谱-串联质谱法测定阿立哌唑、脱氢阿立哌唑和奥氮平的血浆浓度。

主要发现

  • 阿立哌唑影响瞳孔收缩:首次给药后引起扩大,随后每次给药后引起收缩,并引起所有瞳孔测量参数变化(P < .05)。
  • 奥氮平仅改变最小瞳孔尺寸(P = .046)。
  • CYP3A、HTR2A、UGT1A1、DRD2和ABCB1基因多态性影响瞳孔大小、收缩起始时间、瞳孔恢复和收缩速度。
  • CYP2D6、CYP3A、CYP1A2、ABCB1和UGT1A1基因多态性显著影响阿立哌唑、脱氢阿立哌唑和奥氮平的药代动力学。

临床怎么用

  • 临床可考虑瞳孔测量法作为评估抗精神病药物治疗期间自主神经活动的无创工具。
  • 对于使用阿立哌唑或奥氮平的患者,基因多态性(如CYP2D6、CYP3A等)可能影响药物暴露,需关注个体差异。

局限性

  • 试验为短期多剂量给药,未涉及长期用药或患者人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Pupillography is a noninvasive and cost-effective method to determine autonomic nerve activity. Genetic variants in cytochrome P450 (CYP), dopamine receptor (DRD2, DRD3), serotonin receptor (HTR2A, HTR2C) and ATP-binding cassette subfamily B (ABCB1) genes, among others, were previously associated with the pharmacokinetics and pharmacodynamics of antipsychotic drugs. Our aim was to evaluate the effects of aripiprazole and olanzapine on pupillary light reflex related to pharmacogenetics. METHODS: Twenty-four healthy volunteers receiving 5 oral doses of 10 mg aripiprazole and 5 mg olanzapine tablets were genotyped for 46 polymorphisms by quantitative polymerase chain reaction. Pupil examination was performed by automated pupillometry. Aripiprazole, dehydro-aripiprazole and olanzapine plasma concentrations were measured by high-performance liquid chromatography-tandem mass spectrometry. RESULTS: Aripiprazole affected pupil contraction: it caused dilatation after the administration of the first dose, then caused constriction after each dosing. It induced changes in all pupillometric parameters (P < .05). Olanzapine only altered minimum pupil size (P = .046). Polymorphisms in CYP3A, HTR2A, UGT1A1, DRD2 and ABCB1 affected pupil size, the time of onset of constriction, pupil recovery and constriction velocity. Aripiprazole, dehydro-aripiprazole and olanzapine pharmacokinetics were significantly affected by polymorphisms in CYP2D6, CYP3A, CYP1A2, ABCB1 and UGT1A1 genes. CONCLUSIONS: In conclusion, aripiprazole and its main metabolite, dehydro-aripiprazole altered pupil contraction, but olanzapine did not have such an effect. Many polymorphisms may influence pupillometric parameters and several polymorphisms had an effect on aripiprazole, dehydro-aripiprazole and olanzapine pharmacokinetics. Pupillography could be a useful tool for the determination of autonomic nerve activity during antipsychotic treatment.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Koller D, Saiz-Rodríguez M, Zubiaur P, et al. The effects of aripiprazole and olanzapine on pupillary light reflex and its relationship with pharmacogenetics in a randomized multiple-dose trial. Br J Clin Pharmacol. 2020. PMID: 32250470. doi:10.1111/bcp.14300

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。